Current partner codePEPTIDESDE
NCT06199960·Phase 3·INTERVENTIONAL

Dual Ovarian Stimulation (Duostim) and Shanghai Protocols in Poor Ovarian Responders

Status

Completed

Phase

Phase 3

Enrollment

116

Locations

1

Results

Not posted

Publications

0

Study summary

What the protocol is testing.

A combination of follicular phase stimulation and luteal phase stimulation in the same cycle, can be a valuable choice in poor responder patients with reduced ovarian reserve, in order to achieve extreme the number of oocytes in a single menstrual cycle. In the present study, the results of two different Double stimulation cycles including shanghai protocol and Duostim protocol in patients with reduced ovarian reserve, compared with each other to help select a more appropriate treatment for this group of patients. The number of retrieved oocytes and the number of obtained embryos and clinical pregnancy from each protocol will be compared as the primary and secondary outcome.

Full detailed description

The proposal of this randomized clinical trial study is a comparison of two different type of double stimulation protocols in patients who meet the POSEIDON (Patient-Oriented Strategies Encompassing IndividualizeD Oocyte Number) stratification (group 4) criteria. In mild double stimualtion (Shanghai protocol), patients will be received Clomiphene citrate 25 mg/day (Ovumid®; Iran Hormone pharmaceutical Co., Iran) co-treatment and letrozole 2.5 mg/day (Femati®, Atipharmed Co., Iran) will be given from cycle day 3. Letrozole is given for 4 days and clomiphene citrate is used daily before the trigger day. Patients take 150 IU of Human menopausal gonadotropin (HMG) (Humegnan®, Darou Pakhsh Co., Iran) every other day beginning on cycle day 6. When one dominant follicle will reach 18 mm, the final triggering will induce 34-36 h after 0.5 cc of Buserelin acetate (CinnaFact®; CinnaGen pharmaceutical Co., Iran) administration. In luteal phase stimulation a total of 225 IU HMG and letrozole 2.5 mg will administered daily from3 to 5 days after oocyte retrieval. Letrozole administration will be stopped when the dominant follicles reached 12 mm. When one dominant follicle will reach 18 mm, the final triggering will be induced with 0.5 cc of Buserelin acetate (CinnaFact®; CinnaGen pharmaceutical Co., Iran). In the double GnRH- antagonist (Duostim protocol), both follicular and luteal phases stimulation will perform with 150-225 IU of recombinant FSH (Gonal-F®, Merck-sereno, Germany) and HMG (Humegnan, Darou Pakhsh Co., Iran) in GnRH antagonist treatment. The follicular stimulation will be started on day 2-3 of the menstrual. Daily administration of 0.25 mg of GnRH antagonist (Cetrotide®, Merck-Serono; Germany) will be started when the leading follicle are 13-14mm and continue until the day of the oocyte trigger. When one follicle reached 17-18 mm ovulation will be triggered with 0.5 cc of Buserelin acetate (CinnaFact®; CinnaGen pharmaceutical Co., Iran) and oocyte retrieval will be performed after 34-36 hours. Five days after the first oocyte retrieval, a GnRH antagonist protocol identical to the first one will start. When at least two follicles reached 17-18 mm, the ovulation will be triggered with a subcutaneous bolus GnRH-agonist and the second oocyte retrieval will be performed. In all of groups all of embryos will be freeze and will be used in subsequent frozen embryo transfer (FET) cycles. Endometrial preparation for FET cycle will perform with hormonal replacement therapy (HRT) cycle protocol.

Interventions

Treatment arms and agents.

OTHER

Doustim protocol

In Duostim group, the follicular stimulation will be started with a fixed dose of 150 IU of rFSH and HMG 75 IU for 4 days. Daily administration of a GnRH antagonist will be started when the leading follicle are 13-14mm in diameter and continue until the day of the trigger of the ovulation. Five days after the first oocyte retrieval second gonadotropin stimulation will be started identical to the first one..

Timeline

From registration to results.

  1. First posted

    Jan 10, 2024

  2. Study start

    Aug 2, 2019

  3. Primary completion

    May 10, 2022

  4. Study completion

    Nov 20, 2023

  5. Results posted

    Not reported

  6. Registry updated

    Jan 10, 2024

Outcomes

What the study measures.

Primary outcomes

Number of MII oocytes

Time frame · Immediately after oocyte puncture

Oocytes that were mature at the time of oocyte collection (Metaphase II)

Secondary outcomes

Number of cleaved embryos

Time frame · 2-3 days after oocyte puncture

2-3 days embryo from fertilization

Number of blastocyst embryos

Time frame · 5 days after oocyte puncture and sperm insemination

The stage the embryo reaches after 5 days in culture from the oocyte retrieval

Clinical pregnancy rate

Time frame · 4-6 weeks after embryo transfer

The observation of gestational sac on ultrasound examination two-three weeks after positive serum βhCG

Fertilization rate

Time frame · 2-5 days after sperm insemination

Percentage of transformation of micro injected oocytes into two pronuclei

Quality of oocytes

Time frame · Immediately after oocyte puncture

Oocyte quality were assessed by embryologist based on The Istanbul consensus workshop (Hum Reprod.2011). Quality of MII oocytes (based on intracytoplasmic and extracytoplasmic abnormalities) was divided into 3 groups; morph, slightly dysmorph, and dysmorph.

Eligibility

Who can take part.

Minimum age
35 Years
Maximum age
45 Years
Sex
FEMALE
Healthy volunteers
No

Inclusion Criteria: 1. Age ≥35 years 2. Antimullerian hormone (AMH) \<1.2 ng/ml and/or Antral follicular count≤5 follicles 3. ≤4 oocyte retrieved from previous ART cycle 4-18.5\<BMI\<30 Exclusion Criteria: 1. Endometriosis (stage III and IV) 2. Myoma with a compression effect 3. Uterine anomalies (Unicorn, Didelphis,etc,….) 4. Male factor infertility with azoospermia, severe oligospermia and oligoasthenospermia, TESE/PESA

Study locations

1 registered sites.

Iran. Showing up to 24 locations stored in the fast local snapshot.

Royan Institute

Tehran, Iran

Publications

Results and literature.

No PMID-linked publications were present in this registry snapshot.

Primary links

Continue at the source.

Related trials

More studies on Cetrorelix.

Related PeptideStat pages

Put the record in context.

Research pages describe evidence. Vendor pages, where available, describe independently tracked research-product listings and are not clinical recommendations.